AstraZeneca

July 6, 2018July 6, 2018

Imfinzi-Chemo Combo Shows Effectiveness in Treating Triple-negative Breast Cancer, Phase 2 Study Shows

News

The combination of Imfinzi (durvalumab) with standard chemotherapy leads to high treatment effectiveness in patients with triple-negative breast cancer (TNBC), a Phase 2 trial shows. The research, “Randomized phase II ... Read more

May 14, 2018May 14, 2018

Study Discovers Mutations That Cause Resistance to Lynparza, Similar Therapies

News

Researchers have identified mutations in the poly (ADP-ribose) polymerase (PARP) gene that cause resistance to the cancer therapy Lynparza (olaparib) and other PARP inhibitors. These mutations could help physicians predict which cancer ... Read more

April 4, 2018

EMA to Decide if Lynparza Can Treat BRCA-mutated Metastatic Breast Cancer Patients

News

The European Medicines Agency has agreed to review an application by AstraZeneca and MSD requesting the approval of Lynparza (olaparib) for the treatment of patients with a difficult-to-treat type of metastatic breast cancer who ... Read more

February 28, 2018February 28, 2018

Verzenio Approved for Postmenopausal Women with HR+, HER2- Advanced Breast Cancer

News

The U.S. Food and Drug Administration approved Eli Lilly‘s Verzenio (abemaciclib) in combination with an aromatase inhibitor as an initial treatment for postmenopausal women with advanced breast cancer. Verzenio is for breast ... Read more

January 15, 2018

FDA Approves Lynparza to Treat BRCA-mutated Metastatic Breast Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Lynparza (olaparib) for a difficult-to-treat form of metastatic breast cancer. Patients with BRCA-mutated, HER2-negative breast cancer who have previously been treated ... Read more

November 17, 2017November 17, 2017

FDA Approves Faslodex in Combo with Verzenio for Women with Advanced Breast Cancer

News

The U.S. Food and Drug Administration (FDA) expanded to use of AstraZeneca’s Faslodex (fulvestrant) to include it in combination with Verzenio (abemaciclib) to treat HR-positive, HER2-negative advanced or metastatic breast ... Read more

November 15, 2017November 15, 2017

European Commission Approves Faslodex-Ibrance Combo for Advanced Breast Cancer

News

The European Commission (EC) has extended the approval of AstraZeneca‘s breast cancer therapy Faslodex (fulvestrant) to be used in combination with Ibrance (palbociclib) for advanced breast cancers. The combination can now be used ... Read more

October 25, 2017

AstraZeneca and Merck Seeking Lynparza Approval in Japan for Certain Breast Cancer Patients

News

AstraZeneca and Merck submitted a new drug application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) seeking the approval of Lynparza (olaparib) tablets for the treatment of patients with unresectable or ... Read more

October 20, 2017October 20, 2017

FDA to Review Lynparza Extension for Certain Advanced Breast Cancer Patients

News

The U.S. Food and Drug Administration (FDA) will review AstraZeneca and Merck‘s application seeking the extension of Lynparza (olaparib) tablets for the treatment of HER-negative metastatic breast cancer patients whose ... Read more

June 6, 2017June 6, 2017

Lynparza Shrinks Breast Cancer Tumors at Double the Rate of Chemo, Study Shows

News

The ovarian cancer therapy Lynparza (olaparib) shrank the tumors of 60 percent of breast cancer patients treated with it, double the figure for standard chemotherapy, according to a study. Lynparza, a PARP ... Read more